111 related articles for article (PubMed ID: 18814768)
1. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
Golay A
Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
3. Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
Scheen AJ; Van Gaal LF
Eur Heart J; 2007 Jun; 28(11):1401-2; author reply 1402. PubMed ID: 17493946
[No Abstract] [Full Text] [Related]
4. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
6. Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
Green JB; Feinglos MN
Curr Diab Rep; 2007 Oct; 7(5):369-75. PubMed ID: 18173970
[TBL] [Abstract][Full Text] [Related]
7. [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
Scheen AJ; Paquot N; Van Gaal LF
Rev Med Suisse; 2008 Aug; 4(168):1812-7. PubMed ID: 18814765
[TBL] [Abstract][Full Text] [Related]
8. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
9. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
Tonstad S
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
[TBL] [Abstract][Full Text] [Related]
10. [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].
Roussel R
Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():33-5. PubMed ID: 17961659
[No Abstract] [Full Text] [Related]
11. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
12. Rimonabant in obese patients with type 2 diabetes.
Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
[No Abstract] [Full Text] [Related]
13. Rimonabant in obese patients with type 2 diabetes.
Shapiro H; Singer P
Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091
[No Abstract] [Full Text] [Related]
14. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Kintscher U
Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
[No Abstract] [Full Text] [Related]
15. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.
Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994
[No Abstract] [Full Text] [Related]
16. Rimonabant: obituary for a wonder drug.
Boekholdt SM; Peters RJ
Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
[No Abstract] [Full Text] [Related]
17. Does rimonabant pull its weight for type 2 diabetes?
Cleland SJ; Sattar N
Lancet; 2006 Nov; 368(9548):1632-4. PubMed ID: 17098066
[No Abstract] [Full Text] [Related]
18. Effect of rimonabant on weight reduction and cardiovascular risk.
Astrup A
Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932
[No Abstract] [Full Text] [Related]
19. [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
Seissler J
MMW Fortschr Med; 2008 May; 150(18):27-31. PubMed ID: 18533605
[No Abstract] [Full Text] [Related]
20. New options for drug treatment of obesity in patients with Type 2 diabetes.
Kennedy RL; Khoo EY
Diabet Med; 2005 Sep; 22 Suppl 4():23-6. PubMed ID: 16109016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
